CA2417500C — Erbb-2 selective small molecule kinase inhibitors
Assigned to Georgetown University Medical Center · Expires 2008-11-18 · 17y expired
What this patent protects
A novel method for erbB-2 kinase inhibition by compounds identified throug h computational modeling and data processing and/or rational and de novo drug design is provided. The compounds bind erbB-2 kinase molecules and can be used as erbB -2 kinase agonists or antagonists. These…
USPTO Abstract
A novel method for erbB-2 kinase inhibition by compounds identified throug h computational modeling and data processing and/or rational and de novo drug design is provided. The compounds bind erbB-2 kinase molecules and can be used as erbB -2 kinase agonists or antagonists. These compounds are useful especially in the treatment of cancer, particularly breast cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.